Dapsone for Acute Ischemia Stroke Study

• Status: Unknown status
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of the study is to get information about the safety and efficacy of treatment with Dapsone to prevent the disability after ischemic Stroke, in patients diagnosed with anterior territory brain infarct.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cidat, S.A. de C.V.
• Collaborator: El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
• Treatments: Dapsone

Criteria

Inclusion Criteria:

• Patients with the clinical diagnosis of an acute cerebrovascular event in in the anterior cerebral territory, within the last 12 hours who match the MRI or axial CT image.

• Patients with 4 o more points of the National Institute of Health Stroke Scale (NIHSS)

• Age older than 18 years, both gender

• Non acute cerebrovascular event previous

• Informed consent signed by patient or relatives

Exclusion Criteria:

• Diagnosed with recurrent diseases like: heart failure; Myocardial Infarction up 8 weeks before; ventrivular arrhythmia diagnosed by ECG; Second-Degree and Third-Degree Atrioventricular Block; or Long QT Syndrome.

• Pregnancy

• Allergic reactions to sulfa medications

• Patients with kidney failure and hepatic insufficiency

• Deficiency of glucose-6-phosphate dehydrogenase diagnosed